153 related articles for article (PubMed ID: 7826609)
21. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
22. p53 protein in low-grade astrocytomas: a study with long-term follow-up.
Iuzzolino P; Ghimenton C; Nicolato A; Giorgiutti F; Fina P; Doglioni C; Barbareschi M
Br J Cancer; 1994 Mar; 69(3):586-91. PubMed ID: 8123492
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
24. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.
Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Otsuka Y; Yamaguchi M; Ohnishi H; Ohtaki S; Noshiro S; Ookawa S; Mikami T; Mikuni N; Honmou O
J Neurosurg Sci; 2018 Jun; 62(3):239-244. PubMed ID: 28079349
[TBL] [Abstract][Full Text] [Related]
26. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas.
Gaiser T; Becker MR; Meyer J; Habel A; Siegelin MD
Neurochem Int; 2009 Jun; 54(7):458-63. PubMed ID: 19428789
[TBL] [Abstract][Full Text] [Related]
27. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
28. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
29. Expression of diagnostic neuronal markers and outcome in glioblastoma.
Donev K; Scheithauer BW; Rodriguez FJ; Jenkins S
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):411-21. PubMed ID: 20298476
[TBL] [Abstract][Full Text] [Related]
30. Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
Tanizaki Y; Sato Y; Oka H; Utsuki S; Kondo K; Miyajima Y; Nagashio R; Fujii K
Pathol Int; 2006 Sep; 56(9):510-5. PubMed ID: 16930331
[TBL] [Abstract][Full Text] [Related]
31. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
32. Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma.
Gandini NA; Fermento ME; Salomón DG; Obiol DJ; Andrés NC; Zenklusen JC; Arevalo J; Blasco J; López Romero A; Facchinetti MM; Curino AC
Tumour Biol; 2014 Mar; 35(3):2803-15. PubMed ID: 24234335
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
34. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.
Järvelä S; Helin H; Haapasalo J; Järvelä T; Junttila TT; Elenius K; Tanner M; Haapasalo H; Isola J
Neuropathol Appl Neurobiol; 2006 Aug; 32(4):441-50. PubMed ID: 16866989
[TBL] [Abstract][Full Text] [Related]
35. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
Reddy PS; Umesh S; Thota B; Tandon A; Pandey P; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Biol Ther; 2008 May; 7(5):663-8. PubMed ID: 18728403
[TBL] [Abstract][Full Text] [Related]
36. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status.
Pratap R; Shousha S
Breast Cancer Res Treat; 1998 May; 49(1):35-9. PubMed ID: 9694609
[TBL] [Abstract][Full Text] [Related]
37. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
38. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas.
Haapasalo H; Sallinen S; Sallinen P; Helén P; Jääskeläinen J; Salmi TT; Paetau A; Paljärvi L; Visakorpi T; Kalimo H
Neuropathol Appl Neurobiol; 1999 Apr; 25(2):134-42. PubMed ID: 10216001
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
